Company profile
AXIM BIOTECHNOLOGIES, INC. CIK 1514946
Ticker
AXIM (OTC)
Industry
Pharmaceutical Preparations
Headquarters
San Diego, CA 92121
Fiscal year end
2023 (FY)
Key Financials
Revenue
$39.5K
Net income
-$8.06M
Total assets
$4.12M
Total liabilities
$11.78M
Stockholders' equity
-$7.66M
Cash & equivalents
$156.5K
Operating income
-$2.75M
Operating cash flow
-$1.03M
Capital expenditures
$0
Fiscal year 2023, via 10-K filed 2024-04-16. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
-6,961.0%
Net margin
-20,395.0%
Free cash flow
-$1.03M
Free cash flow margin
-2,607.7%
Liabilities / assets
285.8%
Equity / assets
-185.8%
CapEx / revenue
0.0%
Operating cash flow / net income
0.13×
Derived from the fiscal year 2023 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2023
$39.5K
-$8.06M
$4.12M
$11.78M
-$7.66M
2022
$8.9K
-$6.24M
$4.21M
$9.04M
-$4.83M
2021
$60.5K
-$16.03M
$5.32M
$7.66M
-$2.34M
2020
$0
-$6.41M
$11.31M
$9.75M
$1.57M
2019
$799.5K
-$6.45M
$1.69M
$8.45M
-$6.76M
Company Details
SIC code
2834
State of incorporation
NV
Active filer
Yes
Most recent SEC filing
Form 15-12G
2024-12-06
Financials filed via
Form 10-K
filed 2024-04-16
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
San Diego, CA 92121
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:17 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.